Kefeng Ding

6.7k total citations · 4 hit papers
185 papers, 3.6k citations indexed

About

Kefeng Ding is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Kefeng Ding has authored 185 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 103 papers in Oncology, 55 papers in Molecular Biology and 48 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Kefeng Ding's work include Colorectal Cancer Screening and Detection (31 papers), Gastric Cancer Management and Outcomes (29 papers) and Colorectal Cancer Surgical Treatments (27 papers). Kefeng Ding is often cited by papers focused on Colorectal Cancer Screening and Detection (31 papers), Gastric Cancer Management and Outcomes (29 papers) and Colorectal Cancer Surgical Treatments (27 papers). Kefeng Ding collaborates with scholars based in China, United Kingdom and United States. Kefeng Ding's co-authors include Xiangxing Kong, Qian Xiao, Kai Jiang, Ying Yuan, Yeting Hu, Wei Lu, Shu Zheng, Honghe Zhang, Liubo Chen and Jia He and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Kefeng Ding

173 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lactylation-driven METTL3-mediated RNA m6A modification promotes immunosuppression of tumor-infiltrating myeloid cells

2022 506 citations Xiangxing Kong, Kefeng Ding et al. profile →
Global trends in incidence, death, burden and risk factors of early-onset cancer from 1990 to 2019

2023 119 citations Jing Sun, Lijuan Wang et al. profile →
Identification of novel protein biomarkers and drug targets for colorectal cancer by integrating human plasma proteome with genome

2023 91 citations Jing Sun, Jianhui Zhao et al. Genome Medicine profile →
Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments

2025 22 citations Yeting Hu, Qian Xiao et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kefeng Ding China	28	1.6k	1.2k	1.2k	538	484	185	3.6k
Side Liu China	33	1.9k 1.2×	1.0k 0.9×	990 0.8×	712 1.3×	541 1.1×	140	3.6k
Yuan Qi China	36	2.0k 1.3×	1.1k 0.9×	1.2k 1.0×	543 1.0×	292 0.6×	201	4.3k
Manuela Zucknick Norway	32	2.3k 1.4×	904 0.8×	1.5k 1.3×	426 0.8×	384 0.8×	122	4.4k
Jasper L.A. Vleugels Netherlands	13	1.4k 0.9×	1.9k 1.6×	940 0.8×	909 1.7×	543 1.1×	27	3.7k
Shinya Sato Japan	42	2.1k 1.3×	1.0k 0.8×	1.1k 0.9×	522 1.0×	555 1.1×	302	5.4k
Yuanqing Ye United States	35	2.2k 1.4×	853 0.7×	1.6k 1.4×	709 1.3×	451 0.9×	150	4.1k
Chi‐Long Chen Taiwan	32	1.3k 0.8×	910 0.8×	680 0.6×	389 0.7×	374 0.8×	106	2.9k
Lei Liang China	30	1.4k 0.9×	965 0.8×	945 0.8×	486 0.9×	518 1.1×	171	3.4k
Ying Liang China	37	2.3k 1.4×	1.2k 1.0×	1.1k 0.9×	416 0.8×	384 0.8×	170	4.1k
Daiming Fan China	37	2.7k 1.6×	889 0.7×	1.1k 0.9×	492 0.9×	452 0.9×	128	4.0k

Countries citing papers authored by Kefeng Ding

Since Specialization

Citations

This map shows the geographic impact of Kefeng Ding's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kefeng Ding with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kefeng Ding more than expected).

Fields of papers citing papers by Kefeng Ding

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kefeng Ding. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kefeng Ding. The network helps show where Kefeng Ding may publish in the future.

Co-authorship network of co-authors of Kefeng Ding

This figure shows the co-authorship network connecting the top 25 collaborators of Kefeng Ding. A scholar is included among the top collaborators of Kefeng Ding based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kefeng Ding. Kefeng Ding is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zheng, Yuyan, Jingjing Zhang, Chao Chen, et al.. (2024). Prophylactic hyperthermic intraperitoneal chemotherapy in T4 colorectal cancer: Can it improve the oncologic prognosis? – A propensity score matching study. European Journal of Surgical Oncology. 50(2). 107958–107958.

Yuan, Ying, Ning Zhu, Xuefeng Fang, et al.. (2024). Updated survival results of BBCAPX-II: Sintilimab combined with bevacizumab and CapeOx as first-line treatment in patients with RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer.. Journal of Clinical Oncology. 42(16_suppl). 3563–3563. 1 indexed citations

Liu, Ping, Yi Xiao, Wenjian Meng, et al.. (2024). Total neoadjuvant treatment with long-course radiotherapy versus concurrent chemoradiotherapy in local advanced rectal cancer with high risk factors (TNTCRT): A multicenter, randomized, open-label, phase 3 trial.. Journal of Clinical Oncology. 42(17_suppl). LBA3511–LBA3511. 3 indexed citations

Ding, Kefeng, Gong Chen, Ye Yao, et al.. (2024). Preoperative (neoadjuvant) therapy with tislelizumab for locally advanced colorectal cancer with high microsatellite instability or deficient mismatch repair: An open-label, single-arm, multicenter phase II study.. Journal of Clinical Oncology. 42(16_suppl). 3599–3599. 3 indexed citations

Sun, Yuhao, Shuai Yuan, Xuejie Chen, et al.. (2023). The Contribution of Genetic Risk and Lifestyle Factors in the Development of Adult-Onset Inflammatory Bowel Disease: A Prospective Cohort Study. The American Journal of Gastroenterology. 118(3). 511–522. 62 indexed citations

Segelov, Eva, Wei Wang, Gwo Fuang Ho, et al.. (2023). LBA29 Aspirin after standard adjuvant therapy for colorectal cancers (ASCOLT): An international, phase III, randomised, placebo-controlled trial. Annals of Oncology. 34. S1269–S1269. 2 indexed citations

Jiao, Ying, Jialiang Li, Xiangyi Kong, et al.. (2023). 600P Effectiveness and safety of rectal arterial infusion chemotherapy combined with anti-PD1 antibody for microsatellite stable locally advanced rectal cancer: Early outcome report of a two-stage, single armed, phase II study (RAIC). Annals of Oncology. 34. S433–S433.

Zhou, Xuan, Qian Xiao, Fangyuan Jiang, et al.. (2023). Dissecting the pathogenic effects of smoking and its hallmarks in blood DNA methylation on colorectal cancer risk. British Journal of Cancer. 129(8). 1306–1313. 14 indexed citations

Xin, Junyi, Mulong Du, Dongying Gu, et al.. (2023). Risk assessment for colorectal cancer via polygenic risk score and lifestyle exposure: a large-scale association study of East Asian and European populations. Genome Medicine. 15(1). 4–4. 24 indexed citations

10.

Yang, Hang, Dongliang Fu, Jiafeng Wang, et al.. (2022). Targeting RAS mutants in malignancies: successes, failures, and reasons for hope. Cancer Communications. 43(1). 42–74. 19 indexed citations

11.

Qian, Huan, et al.. (2022). Experiences and Challenges of Emerging Online Health Services Combating COVID-19 in China: Retrospective, Cross-Sectional Study of Internet Hospitals. JMIR Medical Informatics. 10(6). e37042–e37042. 19 indexed citations

12.

Weng, Chunhua, Haojie Dong, Rongpan Bai, et al.. (2022). Angiogenin promotes angiogenesis via the endonucleolytic decay of miR-141 in colorectal cancer. Molecular Therapy — Nucleic Acids. 27. 1010–1022. 12 indexed citations

13.

Tian, Yu, et al.. (2021). Improving the Prognosis of Colon Cancer through Knowledge‐Based Clinical‐Molecular Integrated Analysis. BioMed Research International. 2021(1). 9987819–9987819. 5 indexed citations

14.

Chen, Chao, Xiaoming Xu, Xiaoxu Ge, et al.. (2021). An Efficient Prognostic Immune Scoring System For Colorectal Cancer Patients With Peritoneal Metastasis. OncoImmunology. 10(1). 1901464–1901464. 16 indexed citations

15.

Zhu, Yingshuang, Yanqin Huang, Yeting Hu, et al.. (2021). Long‐term risk of colorectal cancer after removal of adenomas during screening colonoscopies in a large community‐based population in China. International Journal of Cancer. 150(4). 594–602. 6 indexed citations

16.

Chen, Chao, Jian Wang, Xiaoxu Ge, et al.. (2020). <p>Factors Prognostic for Peritoneal Metastases from Colorectal Cancer Treated with Surgery</p>. Cancer Management and Research. Volume 12. 10587–10602. 3 indexed citations

17.

Tian, Yu, et al.. (2020). Improving prediction performance of colon cancer prognosis based on the integration of clinical and multi-omics data. BMC Medical Informatics and Decision Making. 20(1). 22–22. 26 indexed citations

18.

Li, Siqi, Xiaoliang Shi, Desen Sun, et al.. (2019). Angiogenin promotes colorectal cancer metastasis via tiRNA production. International Journal of Cancer. 145(5). 1395–1407. 80 indexed citations

19.

Tian, Yu, et al.. (2018). POPCORN: A web service for individual PrognOsis prediction based on multi-center clinical data CollabORatioN without patient-level data sharing. Journal of Biomedical Informatics. 86. 1–14. 11 indexed citations

20.

Zhou, Jiaojiao, Jun Li, Yongmao Song, et al.. (2011). Fast track multi-discipline treatment (FTMDT trial) versus conventional treatment in colorectal cancer--the design of a prospective randomized controlled study. BMC Cancer. 11(1). 494–494. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact